Public health licensing to increase access and facilitate innovation: the Medicines Patent Pool model
Marie-Paule Kieny, Chair of the MPP Governance Board, gives an introduction of an article authored by Philippe Douste-Blazy; Charles Gore; Lelio Marmora; and herself, where they review the impact of the MPP and how its model can be adapted to other disease areas.
The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate
The MPP published in May a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Geneva, 10 July 2019 – This week the World Health Organization (WHO) released its newly updated 21st WHO Model List of Essential Medicines (EML) and 7th WHO Model List of Essential Medicines for children (EMLc), in which key treatments and combinations licensed to the MPP have now been included, namely hepatitis C treatment glecaprevir/pibrentasvir (G/P), antiretroviral regimen tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) and HIV medicine dolutegravir 50mg for children above 25kg.
“Putting an end to the hepatitis epidemic remains a huge challenge in developing countries so we are very pleased that G/P has been added to the WHO’s Essential Medicines Lists,” said Charles Gore, Executive Director of MPP. "This all-oral, once-daily, pan-genotypic combination regimen is an important new option for people living with chronic hepatitis C.”
“We want people living with HIV in low- and middle-income countries to have access to the best possible treatment at the same time as patients in high-income...
Agenda item 11.7, document A72/17 (Access to medicines and vaccines)
Speaker: Liudmyla Maistat
The Medicines Patent Pool (MPP) welcomes the WHO Road Map for Access to medicines, vaccines and other health products.
We note that one of the deliverables which is anticipated to have significant impact on fostering innovation and access to health products is the promotion of public health-oriented licensing agreements and transparency regarding patent status of existing and new health technologies.
We agree that for licensing to become an effective vehicle for access, it must closely align with public health principles and be a part of a broader public health approach to improving access to safe, effective and affordable essential medicines. Over the past nine years, the MPP is proud to have become a key driver of public health-oriented and transparent licensing agreements for improved access to medicines in low- and middle-income countries. Over 100 countries have already benefitted from access to new...
Geneva, 17 May 2019 – In a joint declaration published today, the Health Ministers of Canada, France, Germany, Italy, Japan, the United Kingdom, the United States, and the European Commissioner for Health and Food Safety, gathered in Paris on 16-17 May, highlighted the importance of improving access to safe, effective, quality, affordable and essential health products and supported the expansion of the Medicines Patent Pool (MPP) to essential medicines.
In 2018, at the request of the international community, the MPP expanded its mandate beyond treatment for HIV, hepatitis C and tuberculosis to other essential medicines. Last week, the MPP published its new framework for prioritising target medicines for in-licensing under its expanded mandate.
“In 2011, the G8 had welcomed the establishment of the Unitaid-funded Patent Pool to facilitate the production of affordable HIV medicines well-adapted for use in resource-poor settings, encouraging the voluntary participation of patent holders” said Charles Gore,...
“The Medicines Patent Pool (MPP), a public health organization funded by Unitaid, has played a significant role in facilitating affordable access to essential medicines in the field of HIV and HCV through its public health oriented licences with originator...”
Unable to load twitter timeline, please allow cookie